Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Complex Karyotypic Abnormalities Detected by Conventional Cytogenetic Analysis More Strongly Predict Survival Than FISH, ZAP70, or IgVH Mutation Status for Previously Treated Patients with CLL.

William G. Wierda, MD, PhD, S. O’Brien, MD, S. Faderl, MD, A. Ferrajoli, MD, G. Garcia-Manero, MD, J. Burger, MD, E. Schlette, MD, L. Abruzzo, MD, PhD, S. Lerner, MS, BA, M. Keating, MB, BS

Blood (2007) 110 (11): 2065.

https://doi.org/10.1182/blood.V110.11.2065.2065

Published: 2007

Journal Articles

Combined Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR), an Active Frontline Regimen for High-Risk Patients with CLL.

William G. Wierda, MD, PhD, S. O’Brien, MD, A. Ferrajoli, MD, S. Faderl, MD, C. Koller, MD, Z. Estrov, MD, G. Garcia-Manero, MD, S. Verstovsek, MD, M. Browning, BSN, ADN, S. Lerner, MS, BA, M. Keating, MB, BS

Blood (2007) 110 (11): 628.

https://doi.org/10.1182/blood.V110.11.628.628

Published: 2007

Journal Articles

Dasatinib (SPRYCEL®) in Patients (pts) with Previously Untreated Chronic Myelogenous Leukemia (CML) in Chronic Phase (CML-CP).

Jorge Cortes, S. O’Brien, D. Jones, G. Borthakur, F. Giles, C. Nicaise, H.M. Kantarjian

Blood (2006) 108 (11): 2161.

https://doi.org/10.1182/blood.V108.11.2161.2161

Published: 2006

Journal Articles

Measurement of Free Circulating Bcr-Abl Fusion Protein and Its Phosphorylation in Patients with Chronic Myeloid Leukemia.

I. Jilani, H. Kantarjian, H. Faraji, M. Gorre, J. Cortes, O. Ottmann, K. Bhalla, S. O’Brien, F. Giles, M. Albitar

Blood (2005) 106 (11): 2006.

https://doi.org/10.1182/blood.V106.11.2006.2006

Published: 2005

Journal Articles

Plasma RNA Is More Reliable Than Peripheral Blood Cells for Monitoring Molecular Response to Imatinib in Patients with Chronic Myeloid Leukemia.

W. Ma, R. Tseng, M. Gorre, I. Jilani, M. Keating, H. Kantarjian, J. Cortes, S. O’Brien, F. Giles, M. Albitar

Blood (2005) 106 (11): 2007.

https://doi.org/10.1182/blood.V106.11.2007.2007

Published: 2005

Journal Articles

Plasma Is a Reliable Source of mRNA for Testing IgVH Mutation Status in Patients with Chronic Lymphocytic Leukemia.

W. Ma, I. Jilani, M. Gorre, M. Keating, H. Chan, R. Tseng, H. Kantarjian, S. O’Brien, F. J. Giles, M. Albitar

Blood (2005) 106 (11): 2949.

https://doi.org/10.1182/blood.V106.11.2949.2949

Published: 2005

Journal Articles

Measurement of HSP90 and HSP70 in CD34-Positive Cells: Lower Levels in Myelodysplastic Syndrome Than in Acute Myeloid Leukemia and Correlation with Clinical Behavior.

M. Gorre, I. Jilani, R. Chang, H. Chan, R. Urcia, M. Keating, H. Kantarjian, E. Estey, S. O’Brien, F. Giles, M. Albitar

Blood (2005) 106 (11): 3426.

https://doi.org/10.1182/blood.V106.11.3426.3426

Published: 2005

Journal Articles

Differences in Histone Acetylation Levels in CD34+ Cells between Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS): Correlation between Higher Levels of Histone 2B Acetylation and Survival in AML.

M. Gorre, I. Jilani, R. Chang, J. Bareng, H. Chan, M. Keating, H. Kantarjian, E. Estey, S. O’Brien, F. Giles, M. Albitar

Blood (2005) 106 (11): 2769.

https://doi.org/10.1182/blood.V106.11.2769.2769

Published: 2005

Journal Articles

4E-Binding Protein 1 (4E-BP1) in CD34+ Cells as Measured by Quantitative Flow Cytometry Is an Independent Prognostic Factor in Patients with Acute Myeloid Leukemia.

M. Gorre, I. Jilani, R. Chang, J. Bareng, H. Chan, M. Keating, H. Kantarjian, E. Estey, S. O’Brien, F. Giles, M. Albitar

Blood (2005) 106 (11): 2772.

https://doi.org/10.1182/blood.V106.11.2772.2772

Published: 2005

Journal Articles

Hemizygous/Homozygous and Heterozygous JAK2 Mutation Detected in Plasma of Patients with Myeloproliferative Diseases: Correlation with Clinical Behavior.

W. Ma, H. Kantarjian, I. Jilani, M. Gorre, F. Giles, J. Cortes, S. Verstovsek, S. O’Brien, M. Keating, M. Albitar

Blood (2005) 106 (11): 2593.

https://doi.org/10.1182/blood.V106.11.2593.2593

Published: 2005

Journal Articles

A Phase I/II Study of AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl, on a Continuous Daily Dosing Schedule in Adult Patients (pts) with Imatinib-Resistant Advanced Phase Chronic Myeloid Leukemia (CML) or Relapsed/Refractory Philadelphia Chromosome (Ph+) Acute Llymphocytic Leukemia (ALL).

Francis Giles, MD, H. Kantarjian, MD, B. Wassmann, J. Cortes, MD, S. O’Brien, MD, C. Tanaka, P. Rae, W. Mietlowski, A. Romano, L. Alland, M. Dugan, M. Albitar, MD, O. Ottmann

Blood (2004) 104 (11): 22.

https://doi.org/10.1182/blood.V104.11.22.22

Published: 2004

Journal Articles

Long-Term Follow-Up of Patients With Chronic Lymphocytic Leukemia (CLL) Receiving Fludarabine Regimens as Initial Therapy

M.J. Keating, S. O’Brien, S. Lerner, C. Koller, M. Beran, L.E. Robertson, E. J Freireich, E. Estey, H. Kantarjian

Blood (1998) 92 (4): 1165–1171.

https://doi.org/10.1182/blood.V92.4.1165

Published: 1998

Journal Articles

Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia

M Beran, H Kantarjian, S O'Brien, C Koller, M al-Bitar, S Arbuck, S Pierce, M Moore, JL Abbruzzese, M Andreeff, M Keating, E Estey

Blood (1996) 88 (7): 2473–2479.

https://doi.org/10.1182/blood.V88.7.2473.bloodjournal8872473

Published: 1996

Journal Articles

National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment

BD Cheson, JM Bennett, M Grever, N Kay, MJ Keating, S O'Brien, KR Rai

Blood (1996) 87 (12): 4990–4997.

https://doi.org/10.1182/blood.V87.12.4990.bloodjournal87124990

Published: 1996

Journal Articles

Treatment of chronic myelogenous leukemia: current status and investigational options [see comments]

HM Kantarjian, S O'Brien, P Anderlini, M Talpaz

Blood (1996) 87 (8): 3069–3081.

https://doi.org/10.1182/blood.V87.8.3069.bloodjournal8783069

Published: 1996

Journal Articles

Growth and biologic properties of karyotypically defined subcategories of adult acute lymphocytic leukemia in mice with severe combined immunodeficiency

S Jeha, H Kantarjian, S O'Brien, Y Huh, P Pisa, N Ordonez, M Beran

Blood (1995) 86 (11): 4278–4285.

https://doi.org/10.1182/blood.V86.11.4278.bloodjournal86114278

Published: 1995

Journal Articles

Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase

S O'Brien, H Kantarjian, M Keating, M Beran, C Koller, LE Robertson, J Hester, MB Rios, M Andreeff, M Talpaz

Blood (1995) 86 (9): 3322–3326.

https://doi.org/10.1182/blood.V86.9.3322.bloodjournal8693322

Published: 1995

Journal Articles

Interferon maintenance therapy for patients with chronic lymphocytic leukemia in remission after fludarabine therapy

S O'Brien, H Kantarjian, M Beran, LE Robertson, C Koller, S Lerner, MJ Keating

Blood (1995) 86 (4): 1298–1300.

https://doi.org/10.1182/blood.V86.4.1298.bloodjournal8641298

Published: 1995

Journal Articles

Advances in the biology and treatment of B-cell chronic lymphocytic leukemia

S O'Brien, A del Giglio, M Keating

Blood (1995) 85 (2): 307–318.

https://doi.org/10.1182/blood.V85.2.307.307

Published: 1995

Journal Articles

2-Chlorodeoxyadenosine therapy in patients with T-cell lymphoproliferative disorders

S O'Brien, R Kurzrock, M Duvic, H Kantarjian, S Stass, LE Robertson, E Estey, S Pierce, MJ Keating

Blood (1994) 84 (3): 733–738.

https://doi.org/10.1182/blood.V84.3.733.733

Published: 1994

NARROW

Complex Karyotypic Abnormalities Detected by Conventional Cytogenetic Analysis More Strongly Predict Survival Than FISH, ZAP70, or IgVH Mutation Status for Previously Treated Patients with CLL.

Combined Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR), an Active Frontline Regimen for High-Risk Patients with CLL.

Dasatinib (SPRYCEL®) in Patients (pts) with Previously Untreated Chronic Myelogenous Leukemia (CML) in Chronic Phase (CML-CP).

Measurement of Free Circulating Bcr-Abl Fusion Protein and Its Phosphorylation in Patients with Chronic Myeloid Leukemia.

Plasma RNA Is More Reliable Than Peripheral Blood Cells for Monitoring Molecular Response to Imatinib in Patients with Chronic Myeloid Leukemia.

Plasma Is a Reliable Source of mRNA for Testing IgVH Mutation Status in Patients with Chronic Lymphocytic Leukemia.

Measurement of HSP90 and HSP70 in CD34-Positive Cells: Lower Levels in Myelodysplastic Syndrome Than in Acute Myeloid Leukemia and Correlation with Clinical Behavior.

Differences in Histone Acetylation Levels in CD34+ Cells between Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS): Correlation between Higher Levels of Histone 2B Acetylation and Survival in AML.

4E-Binding Protein 1 (4E-BP1) in CD34+ Cells as Measured by Quantitative Flow Cytometry Is an Independent Prognostic Factor in Patients with Acute Myeloid Leukemia.

Hemizygous/Homozygous and Heterozygous JAK2 Mutation Detected in Plasma of Patients with Myeloproliferative Diseases: Correlation with Clinical Behavior.

A Phase I/II Study of AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl, on a Continuous Daily Dosing Schedule in Adult Patients (pts) with Imatinib-Resistant Advanced Phase Chronic Myeloid Leukemia (CML) or Relapsed/Refractory Philadelphia Chromosome (Ph+) Acute Llymphocytic Leukemia (ALL).

Long-Term Follow-Up of Patients With Chronic Lymphocytic Leukemia (CLL) Receiving Fludarabine Regimens as Initial Therapy

Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia

National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment

Treatment of chronic myelogenous leukemia: current status and investigational options [see comments]

Growth and biologic properties of karyotypically defined subcategories of adult acute lymphocytic leukemia in mice with severe combined immunodeficiency

Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase

Interferon maintenance therapy for patients with chronic lymphocytic leukemia in remission after fludarabine therapy

Advances in the biology and treatment of B-cell chronic lymphocytic leukemia

2-Chlorodeoxyadenosine therapy in patients with T-cell lymphoproliferative disorders

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only